Regeneron Pharmaceuticals Inc (REGN)
502.60
+7.96 +1.61%
NASDAQ
Apr 16, 20:00
USD
Regeneron Pharmaceuticals PE Ratio:
16.39 for April 16, 2021View 4,000+ financial data types
Browse...
View Full Chart
PE Ratio Chart
Export Data
Save Image
Print Image
For advanced charting, view our full-featured
Fundamental Chart
Historical PE Ratio Data
View and export this data going back to 2004.
Start your Free Trial
Export Data
Date Range:
| Data for this Date Range | |
|---|---|
| April 16, 2021 | 16.39 |
| April 15, 2021 | 16.13 |
| April 14, 2021 | 15.69 |
| April 13, 2021 | 15.55 |
| April 12, 2021 | 15.42 |
| April 9, 2021 | 15.49 |
| April 8, 2021 | 15.53 |
| April 7, 2021 | 15.71 |
| April 6, 2021 | 15.61 |
| April 5, 2021 | 15.80 |
| April 1, 2021 | 15.49 |
| March 31, 2021 | 15.43 |
| March 30, 2021 | 15.35 |
| March 29, 2021 | 15.70 |
| March 26, 2021 | 15.55 |
| March 25, 2021 | 15.11 |
| March 24, 2021 | 15.01 |
| March 23, 2021 | 15.32 |
| March 22, 2021 | 15.76 |
| March 19, 2021 | 15.45 |
| March 18, 2021 | 15.48 |
| March 17, 2021 | 16.17 |
| March 16, 2021 | 15.72 |
| March 15, 2021 | 15.78 |
| March 12, 2021 | 15.37 |
| March 11, 2021 | 15.32 |
| March 10, 2021 | 15.26 |
| March 9, 2021 | 15.34 |
| March 8, 2021 | 15.10 |
| March 5, 2021 | 15.05 |
| March 4, 2021 | 14.65 |
| March 3, 2021 | 14.57 |
| March 2, 2021 | 14.83 |
| March 1, 2021 | 15.10 |
| Feb. 26, 2021 | 14.69 |
| Feb. 25, 2021 | 14.78 |
| Feb. 24, 2021 | 14.95 |
| Feb. 23, 2021 | 15.26 |
| Feb. 22, 2021 | 15.02 |
| Feb. 19, 2021 | 15.34 |
| Feb. 18, 2021 | 15.55 |
| Feb. 17, 2021 | 15.71 |
| Feb. 16, 2021 | 15.67 |
| Feb. 12, 2021 | 15.83 |
| Feb. 11, 2021 | 15.99 |
| Feb. 10, 2021 | 16.02 |
| Feb. 9, 2021 | 16.00 |
| Feb. 8, 2021 | 16.14 |
| Feb. 5, 2021 | 16.27 |
| Feb. 4, 2021 | 16.26 |
There is no data for the selected date range.
An error occurred. Please try again by refreshing your browser or contact us with details of your problem.
Advertisement
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS (ttm). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Benchmarks
| Moderna Inc | -- |
| Gilead Sciences Inc | 835.88 |
| Johnson & Johnson | 29.44 |
PE Ratio Range, Past 5 Years
| Minimum | 14.18 | Jun 06 2019 |
| Maximum | 68.54 | Aug 03 2016 |
| Average | 32.18 |
PE Ratio Related Metrics
| PS Ratio | 6.787 |
| PEG Ratio | 0.2478 |
| Price to Book Value | 4.884 |
| Price to Free Cash Flow | 28.79 |
| Price | 502.60 |
| Earnings Yield | 6.10% |
| Market Cap | 53.84B |
| PEGY Ratio | 0.2478 |
| Operating PE Ratio | 16.13 |
| Normalized PE Ratio | 16.39 |
News
Biotech Stock Roundup: GILD's UC Drug Approval, REGN's COVID-19 Antibody Data & More
Yahoo 04/15 08:18 ET
Yahoo 04/15 08:18 ET
UPDATE 1-Swiss gov't looks to boost domestic COVID-19 vaccine, therapy production
Yahoo 04/14 11:34 ET
Yahoo 04/14 11:34 ET
Advertisement
